Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The clinical finding that depressive disorders are often associated with desynchronization of internal rhythms has encouraged the idea that resetting normal circadian rhythms may have antidepressant potential. Agomelatine, a naphthalene analog of melatonin, is both an agonist of human cloned melatonergic MT1 and MT2 receptors and a serotonin 5-HT2C receptor antagonist. Agomelatine combines zeitgeber (synchroniser of the circadian system) activity with neurotransmitter augmentation properties (enhances the levels of dopamine and noradrenaline in frontal cortex). The efficacy of agomelatine in treating depression has been shown in three short-term, pivotal, randomized, placebo–controlled studies. These studies have demonstrated agomelatine to be efficacious in Major Depressive Disorder at the standard dose of 25 mg/day, with the possibility of increasing doses to 50 mg/day in those patients with insufficient improvement. The number of adverse events during the treatment period was comparable to placebo. Four studies have shown the positive effect of agomelatine on sleep continuity and quality and shortening of sleep latency. Despite these promising data, further studies are needed to examine agomelatine's efficacy over a longer treatment period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130 · cited 1×
“Depressed patients also show poor physical health, including coronary heart disease, cerebrovascular disorders, respiratory infections and pain [54].”
BackgroundAction Spectrum for Melatonin Regulation in Humans: Evidence for a Novel Circadian Photoreceptor
Brainard, G. C., Hanifin, J. P., Greeson, J. M., Byrne, B., Glickman, G., Gerner, E., & Rollag, M. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-06405.2001 · Cited by 1,930 · cited 1×
“Circadian pacemaker regulation is also determined by neurotransmitter function and by the phase shifting effects of various chemical or pharmacological components, including melatonin (N-acetyl-5-methoxytryptamine) [4].”
BackgroundSleep and Psychiatric Disorders: A Meta-analysis
Benca, R. M. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080059010 · Cited by 1,468
Risk Factors for Depression Among Elderly Community Subjects: A Systematic Review and Meta-Analysis
Cole, M. G., & Dendukuri, N. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1147 · Cited by 1,368
Hattar, S., Lucas, R. J., Mrosovsky, N., Thompson, S., Douglas, R. H., Hankins, M. W., Lem, J., Biel, M., Hofmann, F., Foster, R. G., et al. (2003) · Nature · doi:10.1038/nature01761 · Cited by 1,245
Tsuno, N., Besset, A., & Ritchie, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1008 · Cited by 1,084
Melatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875 · cited 3×
“Agomelatine has shown anxiolytic properties in animal models of anxiety [37], including the elevated plus maze paradigm, the Vogel conflict test and social defeat, and may, therefore, be expected to have putative benefit in the treatment of anxiety disorders [33,43].”
BackgroundAlonso, J., Angermeyer, M. C., & Lépine, J. P. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00325.x · Cited by 758
CIRCADIAN RHYTHMS: Basic Neurobiology and Clinical Applications
Moore MD, R. Y. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.253 · Cited by 400
Circadian Rhythm Mechanisms in Affective Illness and in Antidepressant Drug Action
Wehr, T., & Wirz-Justice*, A. (1982) · Pharmacopsychiatry · doi:10.1055/s-2007-1019506 · Cited by 256
Cited by
Sexual Dysfunction, Depression, and the Impact of Antidepressants
Kennedy, S. H., & Rizvi, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819c76e9 · Cited by 338
Stahl, S. M., Fava, M., Trivedi, M. H., Caputo, A., Shah, A., & Post, A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05471blu · Cited by 262
Coogan, A. N., & McGowan, N. M. (2017) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-016-0214-5 · Cited by 208
Martino, M., Rocchi, G., Escelsior, A., & Fornaro, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604542 · Cited by 111
“Agomelatine, a novel melatonergic MT1 and MT2 receptors agonist and a 5-HT2C receptor antagonist [354], seems to stimulate IL-2 production, like melatonin, via MT1 receptor agonism in human lymphocytes [355]; chronic administration modulates chronobiological rhythms, including temporal organization of cortisol secreti…”
BackgroundRole of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Metadata
- Authors
- San, L., & Arranz, B.
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2008-09
- Volume
- 23
- Issue
- 6
- Pages
- 396-402
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W2011253374
- Cited by
- 117
- References
- 12
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. https://app.cochat.ai/papers/10.1016/j.eurpsy.2008.04.002
- The paper
- San, L., & Arranz, B. (2008). Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2008.04.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.